<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="1-part\PMC6631207\results\search\disease\results.xml">
  <result pre="or in vitro against viral replication and and/or ZIKV-induced neurotoxicity." exact="microcephaly" post="arbovirus flavivirus drug development neurodevelopment therapy drug screening pregnancy"/>
  <result pre="neurodevelopment therapy drug screening pregnancy Food and Drug Administration (FDA)" exact="encephalitis" post="1. Introduction Zika virus (ZIKV) has been known since"/>
  <result pre="reported in newborn babies exposed to ZIKV in uterus, being" exact="microcephaly" post="the most severe outcome. Infants who develop ZIKV-induced microcephaly"/>
  <result pre="being microcephaly the most severe outcome. Infants who develop ZIKV-induced" exact="microcephaly" post="show recurrent seizures [3], and severely compromised neuropsychomotor development"/>
  <result pre="Extensive research has focused on unraveling the mechanisms of congenital" exact="microcephaly" post="induced by ZIKV [6,7,8]. However, increasing evidence from clinical"/>
  <result pre="dystonic movement, and impaired fine motor skills [9,10,11]. Post-natal onset" exact="microcephaly" post="was also reported, and studies suggest that 60% of"/>
  <result pre="show that ZIKV infection in adult patients may result in" exact="encephalitis" post="[18,19,20], encephalomyelitis [18,20], acute myelitis [18,19], chronic inflammatory demyelinating"/>
  <result pre="ZIKV infection in adult patients may result in encephalitis [18,19,20]," exact="encephalomyelitis" post="[18,20], acute myelitis [18,19], chronic inflammatory demyelinating polyneuropathy [21],"/>
  <result pre="adult patients may result in encephalitis [18,19,20], encephalomyelitis [18,20], acute" exact="myelitis" post="[18,19], chronic inflammatory demyelinating polyneuropathy [21], and Guillain-Barre syndrome"/>
  <result pre="may result in encephalitis [18,19,20], encephalomyelitis [18,20], acute myelitis [18,19]," exact="chronic inflammatory demyelinating polyneuropathy" post="[21], and Guillain-Barre syndrome [19,22,23] (Figure 1B). Episodes of"/>
  <result pre="encephalitis [18,19,20], encephalomyelitis [18,20], acute myelitis [18,19], chronic inflammatory demyelinating" exact="polyneuropathy" post="[21], and Guillain-Barre syndrome [19,22,23] (Figure 1B). Episodes of"/>
  <result pre="northeast of Brazil, epidemiological studies showed that higher incidence of" exact="microcephaly" post="was observed in districts with lower developmental index, higher"/>
  <result pre="potential of sofosbuvir (SFB), an antiviral prodrug clinically used against" exact="hepatitis" post="C virus (HCV), to inhibit ZIKV replication [100,101]. Later,"/>
  <result pre="American ZIKV strains in different in vitro models: placental and" exact="neuroblastoma" post="cell lines, human fetal-derived neuronal stem cells, induced-pluripotent neural"/>
  <result pre="cause excitotoxicity in the brain and contribute to further aggravate" exact="neurodegeneration" post="[94]. Based on such assumption, Costa and colleagues showed"/>
  <result pre="development (Balasubramanian, 2017). AQ has been used for treatment of" exact="malaria" post="in pediatric settings, but serious adverse effects were shown"/>
  <result pre="function of viral RNA polymerase of several viruses such as" exact="measles" post="and rabies [131]. One specific adenosine analog, NITD008, has"/>
  <result pre="viral RNA polymerase of several viruses such as measles and" exact="rabies" post="[131]. One specific adenosine analog, NITD008, has been proven"/>
  <result pre="action is BCX4430 (Galidesivir), which showed strong antiviral activity against" exact="yellow fever" post="and several others viruses in previous studies, and was"/>
  <result pre="(RIB) is a nucleoside analogue used for the treatment of" exact="hepatitis" post="C. In an early report, RIB was able to"/>
  <result pre="of Zika virus from amniotic fl uid of fetuses with" exact="microcephaly" post="in Brazil: A case studyLancet Infect Dis20161665366010.1016/S1473-3099(16)00095-526897108 36.YuanL.HuangX.-Y.LiuZ.-Y.ZhangF.ZhuX.-L.YuJ.-Y.JiX.XuY.-P.LiG.LiC.et al.A"/>
  <result pre="distributed among human populations?PLoS Biol.201816e200659210.1371/journal.pbio.200659230142150 75.de OliveiraW.K.de FranÃ§aG.V.A.CarmoE.H.DuncanB.B.de Souza KuchenbeckerR.SchmidtM.I.Infection-related" exact="microcephaly" post="after the 2015 and 2016 Zika virus outbreaks in"/>
  <result pre="Prevents Neuronal Death Induced by Zika Virus InfectionMBio20178e00350-1710.1128/mBio.00350-1728442607 95.CairnsD.M.BoorguD.S.S.K.LevinM.KaplanD.L.Niclosamide rescues" exact="microcephaly" post="in a humanized in vitro model of Zika infection"/>
  <result pre="agent, demonstrates antitumor activity by blocking multiple signaling pathways of" exact="cancer" post="stem cellsChin. J. Cancer20123117818410.5732/cjc.011.1029022237038 126.collab: BayerYomesan (Package Insert)BayerLeverkusen, Germany1988"/>
 </snippets>
</snippetsTree>
